Iga Swiatek's Doping Case Stirs Debate Over Fairness in Tennis

The Polish star served a one-month ban for a contaminated substance, raising questions about consistency in anti-doping rulings.

Iga Swiatek tested positive for trimetazidine in August 2024, which was traced to contamination in her melatonin medication.
The International Tennis Integrity Agency (ITIA) ruled her fault as minimal, leading to a one-month ban, but critics have questioned the leniency of the penalty.
Simona Halep and other players have alleged preferential treatment, contrasting Swiatek's case with harsher bans for similar violations in the past.
The World Anti-Doping Agency (WADA) is reviewing the ITIA's decision and may appeal to the Court of Arbitration for Sport (CAS) for stricter sanctions.
Swiatek has defended her innocence, highlighting procedural differences in anti-doping cases and expressing trust in the ITIA's objectivity.